



Publikationen 2007 - 2010 Forschungsbereichs ProQinase Klinik für Tumorbiologie

Dr. Christoph Schächtele

2010

Artikel (Autoren aus dem Forschungsbereich ProQinase sind fett gedruckt)

Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, **Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MHG**, Baumann K, Kunick C (2010): Identification of 2-Anilino-9-methoxy-5,7-dihydro-6*H*-pyrimido[5,4-*d*][1] benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation.
Journal of Medicinal Chemistry 53, 2433-2442

Elsadek B, **Graeser R**, Warnecke A, Unger C, Saleem T, El-Melegy N, Madkor H, Kratz F (2010): Optimization of an Albumin-Binding Prodrug of Doxorubicin That Is Cleaved by Prostate-Specific Antigen.
ACS Medicinal Chemistry Letters 1, 234-238

Fichtner I, Claffey J, Deally A, Gleeson B, Hogan M, Markelova MR, Mueller-Bunz H., **Weber H**, Tacke M (2010): Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted caki-1 tumors in mice.
Journal of Organometallic Chemistry 695, 1175-1181

Fürst R, **Zirrgiebel U, Totzke F**, Zahler S, Vollmar AM, Koch E (2010): The Crataegus extract WS[®] 1442 inhibits balloon catheter-induced intimal hyperplasia in the rat carotid artery by directly influencing PDGFR- β .
Atherosclerosis 211, 409-417

Graeser R, Esser N (2010): Bioluminescence *in vivo* imaging of orthotopically implanted tumor cells in the preclinical drug discovery. In: 3D Imaging: Theory, Technology and Applications.
Nova Science Publishers, Inc. Chapter 5

Graeser R, Fiedler U, Esser N, Klotzbuecher A, Weber H, Schächtele C (2010): The Potency of Refined Mouse Models: Implications for Clinical Trials.
Current Cancer Therapy Reviews 6, 62-80

Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Müller MJ, Greschik H, Kirfel J, Ji S, Kunowska N, **Beisenherz-Huss C**, Günther T, Buettner R, Schüle R (2010): Phosphorylation of histone H3T6 by PKC β_1 controls demethylation at histone H3K4.
nature [Advanced online publication]

Piersma SR, **Fiedler U**, Span S, **Lingnau A**, Pham T, **Hoffmann S, Kubbutat MHG**, Jimenez C (2010): Workflow comparison for in-depth, quantitative secretome proteomics for cancer biomarker discovery: Method evaluation, differential analysis and verification in serum.
Journal of Proteome Research 9, 1913-1922

Shi C, Xu MJ, Bayer M, Deng ZW, **Kubbutat MHG**, Waejen W, Proksch P, Lin WH (2010): Phenolic compounds and their anti-oxidative properties and protein kinase inhibition from the Chinese mangrove plant *Laguncularia racemosa*
Phytochemistry 71, 435-442

Sroka IM, Heiss EH, Havlicek L, **Totzke F**, Aristei Y, Pechan P, **Kubbutat MHG**, Strnad M, Dirsch VM (2010): A Novel Roscovitine Derivative Potently Induces G₁-Phase Arrest in Platelet-Derived Growth Factor-BB-Activated Vascular Smooth Muscle Cells.
Molecular Pharmacology 77, 255-261

Thomas M, Felcht M, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, Rohr K, Benest AV, **Fiedler U**, Augustin HG (2010): Angiopoietin-2 stimulation of endothelial cells induces $\alpha v \beta 3$ integrin internalization and degradation.
Journal of Biological Chemistry [Epub ahead of print June 2]

Poster

Budde P, Prinz T, **Fiedler U**, **Klotzbücher A**, Kuhn K, Baumann C, Selzer S, Herfelder D, Boehme KA, Volkmer H, **Kubbutat MHG**, Zucht HD (2010): BioTag: Identification of Protein Biomarkers Indicating Treatment Effects of Protein kinase Inhibitors
Cancer Proteomics, June 8-9, Berlin, Germany

Ebada SS, Chovolou Y, Wätjen W, Wray V, Edrada R, **Kubbutat MHG**, Proksch P (2010): Protein Kinase Inhibiting Anthraquinones and NF- κ B Inhibiting
58th International Congress of the Society for Medicinal Plant and Natural Product Research, August 29 - September 2, Berlin, Germany

Graeser R, **Birkle M**, Rentsch C, **Schaechtele C** (2010): A combined IHC/Western method to measure phosphorylated histone H3 in skin biopsies as potential biomarker for anticancer drug action
101st Annual Meeting of AACR, April 17-21, Washington, USA

Lemcke T, Rarey M, Dreher J, **Totzke F**, **Schächtele C**, **Kubbutat MHG**, Kunick C (2010): Identification of Inhibitors of the Tyrosine Kinase c-Met by Structure-Based Virtual Screening
18th European Symposium on Quantitative Structure-Activity Relationships, September 19-24, Rhodes, Greece

Lingnau A, **Feger D**, **Hoffmann S**, **Umber S**, **Kubbutat MHG** (2010): A novel human AML bone marrow engraftment mouse model using luciferase expressing MOLM13 cells
5th Annual Cell-Based Assays Conference, June 8-9, Cologne, Germany

2009

Artikel (Autoren aus dem Forschungsbereich ProQinase sind fett gedruckt)

Ajaj AK, **Graeser R**, Fichtner I, Kratz F (2009): In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Cancer Chemother Pharmacol, Feb 20. [Epub ahead of print]

Caballero M, Scheele J, **Zirrgiebel U**, **Esser N**, **Schaechtele C**, Soltan J, Rentschler J, Diergarten K, Dreys J (2009): Anti-tumor effects of AMT in the renal cell carcinoma model.
Oncology Reports 23, 205-210

Calderón M, **Graeser R**, Kratz F, Haag R (2009): Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol.
Bioorganic & Medicinal Chemistry Letters 19, 3725-3728

Debbab A, Aly AH, Edrada-Ebel R, Wray V, Mueller WE, **Totzke F**, **Zirrgiebel U**, **Schaechtele C**, **Kubbutat MHG**, Lin WH, Mosaddak M, Hakiki A, Proksch P, Ebel R (2009): Bioactive Metabolites the Endophytic Fungus *Stemphylium globuliferum* Isolated from *Mentha pulegium*.
Journal of Natural Products, [Epub ahead of print]

Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, **Zirrgiebel U**, Robertson JD, Puchalski TA, Collins B, Juergensmeier JM, Serve (2009): An open-label, Phase I study of cediranib (RECENTINTM) in patients with acute myeloid leukemia.
Leukemia Research, [Epub ahead of print]

Graeser R, **Esser N**, Unger H, Fichtner I, Zhu A, Unger C, Kratz F (2009): INNO-206, the (6-maleimidocaproyl) hydrazone derivative of doxorubicin, shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Invest New Drugs, Jan 8. [Epub ahead of print]

Graeser R, Bornmann C, **Esser N**, Ziroli V, Jantschke P, Unger C, Hopt UT, Schaechtele C, von Dobschuetz E, Massing U (2009): Antimetastatic Effects of Liposomal Gemcitabine and Empty Liposomes in an Orthotopic Mouse Model of Pancreatic Cancer.
Pancreas, Jan 11. [Epub ahead of print]

Jantschke P, Zirolu V, **Esser N, Graeser R**, Kluth J, Sukolinskays A, Taylor LA, Unger C, Massing U (2009): Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Clinical & Experimental Metastasis 26, 984-992

Kalén M, Wallgard E, Asker N, Nasevicius A, Athley E, Billgren E, Larson JD, Wadman SA, Norseng E, Clark KJ, He L, Karlsson-Lindahl L, Häge A-K, **Weber H**, Augustin HG, Samuelsson T, Kemmet CK, Utesch CM, Essner JJ, Hackett PB, Hellström M (2009): Combination of Reverse and Chemical Genetic Screens Reveals Angiogenesis Inhibitors and Targets.

Chemistry & Biology 16, 432-441

Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, **Fiedler U**, Augustin HG (2009): Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth.

Cancer Research 69, 1324-1333

Peifer C, Buehler S, Hauser D, Kinkel K, **Totzke F, Schachtele C**, Laufer S (2009): Design, synthesis and characterization of N₉/N₇-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors.

Eur J Med Chem. 44, 1788-1793

Tasler S, Mueller O, Wieber T, Herz T, Krauss R, **Totzke F, Kubbutat MHG, Schaechtele C** (2009): N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: Hit identification and scaffold hopping.

Bioorganic & Medicinal Chemistry Letters 19, 1349-1356

Tasler S, Mueller O, Wieber T, Herz T, Pegoraro S, Saeb W, Lang M, Krauss R, **Totzke F, Zirrgiebel U, Ehlert JE, Kubbutat MHG, Schaechtele C** (2009): Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization.

Bioorganic & Medicinal Chemistry Letters 17, 6728-6737

Waetjen W, Putz A, Chovolou Y, Kampkötter A, **Totzke F, Kubbutat MHG**, Proksch P, Konuklugil B (2009): Hexa-, hepta- and nonaprenylhydroquinones isolated from marine sponges *Sarcotragus muscarum* and *Ircinia fasciculata* inhibit NF- κ B signalling in H4IIE cells.

Journal of Pharmacy and Pharmacology 61, 919-924

Waetjen W, Debbab A, Hohfeld A, Chovolou Y, Kampkoetter A, Edrada RA, Ebel R, Hakiki A, Mosaddak M, **Totzke F, Kubbutat MHG**, Proksch P (2009): Enniatins A1, B and B1 from an endophytic strain of *Fusarium tricinctum* induce apoptotic cell death in H4IIE hepatoma cells accompanied by inhibition of ERK phosphorylation.

Molecular Nutrition & Food Research 53, 431-440

Xu S, Luo Y, **Graeser R**, Warnecke A, Kratz F, Hauff P, Licha K, Haag R (2009): Development of pH-responsive core-shell nanocarriers for delivery of therapeutic and diagnostic agents.

Bioorganic & Medicinal Chemistry Letters 19, 1030-1034. Epub 2008 Jan 18.

Poster

DetermannR, **Totzke F, Schaechtele C, Kubbutat MHG**, Preu L, Kunick C (2009): 2-ANILINO-4-(BENZIMIDAZOL-2-YL)PYRIMIDINES: A SERIES OF NOVEL MULTIKINASE INHIBITORS
DPHG Jahrestagung, September 29-October 1, Jena, Germany

Ehlert J, Mutschler B, Mueller M, Feger D, Umber S, Weber H, Ziegler D, Schaechtele C, Kubbutat MHG (2009): Profiling of kinase inhibitors Lapatinib, Tozasertib, Sorafenib, Sunitinib, Erlotinib, Gefitinib and Vatalanib in cellular phosphorylation assays.
100th Annual Meeting of AACR, April 18-22, Denver, USA

Esser N, Graeser R, Fiedler U, Yu T, Mueller I, **Schaechtele C** (2009): Impressive Antitumoral, Antimetastatic and Antiangiogenic activity of the Thrombin Inhibitor Revasc in an orthotopic mouse model of pancreatic cancer.
AACR-NCI-EORTC, November 15-19, Boston, USA

Esser N, Fiedler U, Graeser R, Yu T, Mueller I, **Schaechtele C** (2009): Antitumor efficacy of PEG-Hirudin (LU 87981), administered three times weekly, in an orthotopic AsPC-1 pancreas carcinoma model.
AACR-NCI-EORTC, November 15-19, Boston, USA

Fiedler U, Lingnau A, Hoffmann S, Piersma SR, Knol JC, Jasper A, Jimenez CR, **Kubbutat MHG** (2009): Identification of protein kinase signaling dependent biomarkers.
Biomarker World Congress, Mai 27-29, Philadelphia, USA

Frost A, Karrasch M, Lilla C, Klinkhardt U, Buechert M, Arends J, **Fiedler U**, Marmé D, Mross K, Fasol U (2009): Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) as a diagnostic tool for early response to antiangiogenic treatment with cationic liposomal paclitaxel (EndoTAGTM-1) in patients suffering from secondary liver tumors.

100th Annual Meeting of AACR, April 18-22, Denver USA

Graeser R, Esser N, Obodozie C, Schaechtele C (2009): Characterization of a novel orthotopic hepatocarcinoma mouse model using luciferase-transduced Alexander cells.

100th Annual Meeting of AACR, April 18-22, Denver, USA

Graeser R, Esser N, Unger H, Unger C, Kratz F (2009): INNO-206 shows superior antitumor efficacy compared to doxorubicin in an orthotopic pancreas carcinoma model.

100th Annual Meeting of AACR, April 18-22, Denver, USA

Krauss R, Lang M, Herz T, Tasler S, Henry C, **Totzke F, Ehlert J**, Zirrgiebel U, **Klotzbücher A, Feger D, Weber H, Kubbutat MHG, Schaechtele C** (2009): 4SC-203, a Novel multi-Target Kinase Inhibitor.

PROTEIN KINASE 2009: Signalling Success, 3rd SCI-RSC Symposium on Kinase Inhibitor Design, May 18-19, AstraZeneca, Cheshire, UK

Lingnau A, Feger D, Hoffmann S, Umber S, Graeser R, Esser N, Schaechtele C, Kubbutat MHG (2009): A novel orthotopic AML mouse using intravenously transplanted luciferase expressing human MOLM-13 cells.

AACR Special Conference "Mouse Models of Cancer, January 12-15, San Francisco, USA

Schmidt S, **Totzke F, Schaechtele C, Kubbutat MHG**, Lemcke T, Preu L, Kunick C (2009): Development of novel dual SRC/IGF-1R inhibitors.

DPhG Jahrestagung, September 29-October 1, Jena, Germany

Schmidt S, **Totzke F, Schaechtele C, Kubbutat MHG**, Lemcke T, Preu L, Kunick C (2009): Dual SRC/IGF-1R inhibitors based on 2-(1*H*-indol-3-yl)-2-oxoacetohydrazide scaffold.

Frontiers in Medicinal Chemistry Conference, October 4-6, Barcelona, Spain

2008

Artikel (Autoren aus dem Forschungsbereich ProQinase sind fett gedruckt)

Alajati A, Laib AM, **Weber H**, Boos AM, Bartol A, Ikenberg K, Korff T, Zentgraf H, **Obodozie C, Graeser R**, Christian S, Finkenzeller G, Stark GB, Héroult M, Augustin H (2008): Spheroid-based engineering of a human vasculature in mice.

Nature Methods 5, 439-445

Aly AH, Edrada-Ebel R, Indriani ID, Wray V, Mueller WE, **Totzke F, Zirrgiebel U, Schaechtele C, Kubbutat MH**, Lin WH, Proksch P, Ebel R (2008): Cytotoxic Metabolites from the Fungal Endophyte *Alternaria* sp. and Their Subsequent Detection in Its Host Plant *Polygonum senegalense*.

J Nat Prod. 71, 972-980

Bornmann C, **Graeser R, Esser N**, Ziroli V, Jantscheff P, Keck T, Unger C, Hopt UT, Adam U, **Schaechtele C**, Massing U, von Dobschuetz E (2008): A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.

Cancer Chemother Pharmacol. 61, 395-405

Danilenko VN, Simonov AY, Lakatosh SA, **Kubbutat MHG, Totzke F, Schaechtele C**, Elizarov SM, Bekker OB, Printsevskaya SS, Luzikov YN, Reznikova MI, Shtil AA, Preobrazhenskaya (2008): Search for Inhibitors of Bacterial and Human Protein kinases among Derivatives of Diazepines[1,4] Annelated with Maleimide and Indole Cycles

J Med Chem. 51, 7731-7736

Doehn C, **Esser N**, Pauels HG, Kießig ST, Stelljes M, Grossmann A, Jocham D, Drevs J (2008): Mode-of-Action, Efficacy, and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma.

European Urology, Jun 4. [Epub ahead of print]

Fichtner I, Claffey J, Gleeson B, Hogan M, Wallis D, **Weber H**, Tacke M (2008): Antitumor Activity of Oxali-Titanocene Y in Xenografted Caki-1 Tumors in Mice.

Letters in Drug Design & Discovery 5, 489-493

Graeser R, Chung DE, **Esser N, Moor S, Schaechtele C**, Unger C, Kratz F (2008): Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).

Int J Cancer 122, 1145-54

Klopper J, Lindenmaier W, **Fiedler U**, Mehlhorn A, Stark GB, Finkenzeller G (2008): High efficient adenoviral-mediated VEGF and Ang-1 gene delivery into osteogenically differentiated human mesenchymal stem cells. *Microvasc Res.* 75, 83-90

Oehmig A, **Klotzbuecher A**, Thomas M, Weise F, Hagner U, Brundiens R, Waldherr D, **Lingnau A**, Knappik A, **Kubbutat MHG**, Joos T, Volkmer H (2008): A novel reverse transduction adenoviral array for the functional analysis of shRNA libraries. *BMC Genomics* 9, 441

Peifer C, Selig R, Kinkel K, Ott D, **Totzke F**, **Schaechtele C**, Heidenreich R, Roecken M, Schollmeyer D, Laufer S (2008): Design, Synthesis and Biological Evaluation of Novel 3-Aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor (VEGF-R) Inhibitors. *J Med Chem.* 51, 3814-24

Pieh C, Agostini H, Buschbeck C, Krueger M, Schulte-Moenting J, **Zirrgiebel U**, Drevs J, Lagrèze WA (2008): VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: Relationship to retinopathy of prematurity. *British Journal of Ophthalmology* 92, 689-693

Puttini M, Redaelli S, Moretti, L, Gunby R, Mologni L, Marchisi E, Cleris L, Donella-Deana A, Drucekes P, Sala E, Lucchini V, **Kubbutat MHG**, Formelli F, Zambon A, Scapozza L, Gambarcorti-Passerini C (2008): Characterisation of CMP-584, an Abl-inhibitor with lasting effects. *Haematologica* 93, 653-661

Soltau J, **Zirrgiebel U**, **Esser N**, **Schaechtele C**, **Totzke F**, Unger C, Merefot I, Drevs J (2008): Antitumoral and Antiangiogenic Efficacy of Bisphosphonates *In Vitro* and in Murine RENCA Model. *Anticancer Research* 28, 933-942

Voigt B, Krug M, **Schaechtele C**, **Totzke F**, Hilgeroth A (2008): Probing Novel 1-Aza-9-oxafluorenes as Selective GSK-3beta Inhibitors. *ChemMedChem.* 3, 120-126

Poster

Egert-Schmidt AM, Preu L, **Totzke F**, **Schaechtele C**, **Kubbutat MHG**, Kunick C (2008): PYRIMIDO[5',4':5,6]PYRIDIO[3,2-d][1]-BENZAZEPINE-6,9,11-TRIONES: A new type of biologically active heterocycles. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, October 8-10, Bonn, Germany

Ehlert J, **Mutschler B**, **Mueller M**, **Lingnau A**, **Hoffmann S**, **Kubbutat MHG** (2008): A test system for assaying inhibitors of the kinase activity of B-Raf V600E in cells and in vivo. 3rd Protein Kinases in Drug Discovery (GTCBIO), May 5-6, San Diego, USA

Feger D, **Umber S**, **Totzke F**, **Zirrgiebel U**, **Lingnau A**, **Schaechtele C**, **Kubbutat MHG** (2008): Cellular phosphorylation assays - important tools for the characterization of protein kinase inhibitors. 7th Annual Protein Kinase Congress, March 11-12, Berlin, Germany

Fiedler U, **Lingnau A**, **Hoffmann S**, Piersma S, Knoll JC, **Jasper A**, Jimenez CR, **Kubbutat MHG** (2008): A novel system to identify target-specific biomarkers. Biomarkers Europe 2008, November 10-11, Vienna, Austria

Fiedler U, **Lingnau A**, **Hoffmann S**, **Jasper A**, **Totzke F**, **Zirrgiebel U**, **Schaechtele C**, **Kubbutat MHG** (2008): Identification of target specific biomarkers to monitor efficient anti-cancer therapies. Keystone Symposia Conference, February 3-8, Tahoe City, USA

Graeser R, **Esser N**, Schillert A, Zeiser R, Jantschke P, Hildenbrand B, Unger C, **Schaechtele C** (2008): Development of an orthotopic colon tumor model using HT29 cells with an endogenous population of CD133/CD44 positive cells. 99th Annual Meeting of AACR, April 12-16, San Diego, USA

Luik S, Goetter M, **Graeser R**, **Schaechtele C**, Laufer S (2008): Development of two microplate or microbead based assay to screen p38 δ MAPK inhibitors. 20th Intern. Symposium on Medicinal Chemistry EFMC-ISMC, Aug. 31 - Sept. 04, Vienna, Austria

Weber W, Weidensteiner C, Reichardt W, von Elverfeldt D, **Siedentopf O**, **Schaechtele C** (2008): Blood flow analysis by magnetic resonance imaging in a human endothelial cell derived *in vivo* angiogenesis model in mice. *Discovery on Target*, October 20-23, Boston USA

2007

Artikel (Autoren aus dem Forschungsbereich ProKinase sind fett gedruckt)

Augustin HG, **Fiedler U (2007)**: Regulation of angiogenesis and vascular homeostasis through the Angiopoietin/Tie system. In: Marmé D, Fusenig N (eds): Tumor Angiogenesis – Basic Mechanism and Cancer Therapy. Springer Verlag, Berlin, pp 109-120

Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, Mateo-Lozano S, Drueckes P, **Schaechtele C, Kubbutat MHG**, Liger F, Marquet B, Joseph B, Echalié A, Endicott JA, Notario V, Meijer L **(2007)**: Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res. 1, 8325-34

Dakas PY, Barluenga S, **Totzke F, Zirrgiebel U**, Winssinger N **(2007)**: Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors. Angew Chem Int Ed Engl. 46, 6899-902

Dreys J, Siegert P, Medinger M, Mross K, Strecker R, **Zirrgiebel U**, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C **(2007)**: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 25, 3045-54

Fiedler U (2007): Die Bedeutung des Tie / Angiopoietin-1 und -2 Rezeptor / Ligand Systems in der Angiogenese. In: Mross K (ed): Angiogeneseforschung in der Medizin. UniMed Verlag, Bremen, pp 35-44

Kohfeld S, Jones PG, **Totzke F, Schaechtele C, Kubbutat MHG**, Kunick C **(2007)**: 1-Aryl-4,6-dihydropyrazolo[4,3-d][1]benzazepin-5(1H)-ones: A new class of antiproliferative agents with selectivity for human leukemia and breast cancer cell lines. Eur J Med Chem. 42, 1317-1324

Zirrgiebel U, Schaechtele C (2007): Surrogatmarker. In: Dreys J (ed): Tumorangio-genese - Grundlagen und therapeutische Ansätze. Uni-Med Verlag, Bremen, pp 30-49

Weber H, Claffey J, Hogan M, Pampillón C, Tacke M **(2007)**: Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay. Toxicol In Vitro. 29

Zahler S, Tietze S, **Totzke F, Kubbutat MHG**, Meijer L, Vollmar AM, Apostolakis J **(2007)**: Inverse in silico screening for identification of kinase inhibitor targets. Chemistry & Biology 14, 1207-14

Poster

Chamrad DC, Bailey S, Wattenberg A, **Beisenherz-Huss C, Graeser R, Müller D**, Blügge M **(2007)**: Systematic PTM Analysis of Protein Kinases Using LC-MS/MS data. ABRF Conference Creating the Biological Roadmap, March 31 - April 3, Tampa, USA

Egert AM, Kohfeld S, **Kubbutat MHG, Schaechtele C, Totzke F**, Zaharevitz DW, Kunick C **(2007)**: 2-Anilino-pyrimido [5,4-d][1]Benzazepin-6-ones: Novel inhibitors of cancer-related protein kinases. Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, October 10-13, Erlangen, Germany

Ehlert JE, Mutschler B, Weber H, Totzke F, Zirrgiebel U, Krauss R, Lang M, Tasler S, **Schaechtele C, Kubbutat MHG (2007)**: A cellular test system for assaying inhibitors of the focal adhesion kinase (FAK). CHI's 5th Protein Kinase Targets Meeting, June 4-6, Boston, USA

Fiedler W, Mesters R, Heuser M, Ehninger G, Ottman OG, Berdel WE, **Zirrgiebel U**, Robertson J, Puchalski TA, Brave SR, Jürgensmeier JM, Serve H **(2007)**: An open, Phase I study of cediranib (RECENTIN™, AZD2171) in patients with acute myeloid leukemia (AML). 49th Annual Meeting and Exposition of the ASH, December 8-11, Atlanta, USA

Graeser R, Bornmann C, **Esser N**, Jantschke P, Zirolì V, Unger C, Hopt UT, von Dobschuetz E, **Schaechtele C**, Massing U **(2007)**: Anti-metastatic activity of liposomes demonstrated on an orthotopic mouse model of pancreatic cancer. 98th Annual Meeting of AACR, April 14-18, Los Angeles, USA

Rohrer S, Dreher J, **Kubbutat MHG, Schaechtele C, Totzke F**, Kunick C, Baumann K **(2007)**: QSAR modelling of kinases inhibition for several structurally diverse compound classes. 3rd Pharmaceutical Sciences World Congress, April 22-25, Amsterdam, The Netherlands

van Herpen CML, Dreys J, van Crujisen H, Voest EE, Punt CJ, Robertson J, Saunders O, **Zirgibel U**, Unger C, Giaccone G (2007): Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): combined results from two Phase I studies. 43rd ASCO Annual Meeting, June 1-5, Chicago, USA

Weber H, Hellström M, Kalen M, Korff T, **Esser N**, and Augustin HG (2007): Large scale screening to identify novel pro- and antiangiogenic compounds using a spheroid based angiogenesis assay. 98th Annual Meeting of AACR, April 14-18, Los Angeles, USA